Last reviewed · How we verify
Placebo coated tablets
Placebo coated tablets contain no active pharmaceutical ingredient and work through the placebo effect, where the expectation of treatment produces therapeutic benefit independent of pharmacological action.
Placebo coated tablets contain no active pharmaceutical ingredient and work through the placebo effect, where the expectation of treatment produces therapeutic benefit independent of pharmacological action. Used for Clinical trial control comparator (non-therapeutic use).
At a glance
| Generic name | Placebo coated tablets |
|---|---|
| Also known as | Placebo |
| Sponsor | Bionorica SE |
| Modality | Small molecule |
| Phase | Phase 3 |
Mechanism of action
Placebo tablets are inert formulations used as control comparators in clinical trials to distinguish true drug efficacy from placebo response. They may produce measurable clinical improvements through psychobiological mechanisms including expectation, conditioning, and activation of endogenous healing pathways. In Phase 3 trials, placebos establish the baseline therapeutic effect against which investigational drugs are evaluated.
Approved indications
- Clinical trial control comparator (non-therapeutic use)
Common side effects
- Placebo response (symptom improvement without active drug)
- Nocebo response (adverse events attributed to inert tablet)
Key clinical trials
- Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (PHASE2, PHASE3)
- A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis (PHASE3)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP (PHASE2)
- A Research Study of VCT220 in Adult Chinese Participants With Obesity (PHASE3)
- Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid Arthritis (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis (PHASE3)
- A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment (PHASE3)
- Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |